Industry + operational reality.
Market analysis, regulatory landscape, and platform commentary for peptide brand operators.
Why Shopify Keeps Banning Peptide Brands in 2026
Shopify, Stripe, and the mainstream e-commerce stack are dropping peptide brands at an accelerating rate. Here's why it's happening and what operators are doing about it.
Read article →The State of Peptide DTC in 2026: Market Growth, Players, and Where It's Going
The peptide DTC market grew 200%+ in 2024-2025, fueled by the GLP-1 wave. Here's what the category looks like in 2026, who's winning, and the structural shifts ahead.
Read article →What the GLP-1 Boom Means for the Rest of the Peptide Market
Semaglutide pulled an entire category into the spotlight. Here's how the GLP-1 wave changed consumer awareness, regulatory scrutiny, and ad platform behavior for every other peptide brand.
Read article →Meta's Restricted-Product Policy, Explained for Peptide Brand Operators
Meta's restricted-product policy is the single biggest reason peptide ad accounts get disabled. Here's what the policy actually says and how Meta enforces it.
Read article →Stripe Alternatives for Peptide Brands in 2026
Stripe drops peptide brands. Here are the payment processors that actually work for the category in 2026 — high-risk credit, bank rails, crypto — plus the tradeoffs.
Read article →The Peptide Brand Compliance Landscape in 2026: Federal, State, and Platform Layers
Three independent compliance regimes apply to every peptide brand: federal (FDA, FTC), state (pharmacy boards, AGs), and platform (Meta, Stripe, Shopify). Here's the current landscape.
Read article →